A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. (Q50561584)
Jump to navigation
Jump to search
scientific article published in February 1998
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. |
scientific article published in February 1998 |
Statements
A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85 (English)
J Overgaard
H S Hansen
M Overgaard
A Berthelsen
B Lindeløv
K Jørgensen
1 February 1998